AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:55:05 26/06/2024 pm IST			5-day change	1st Jan Change
12,519 ^GBX	-0.25%		+1.47%	+18.13%

01:57pm	ASTRAZENECA : Deutsche Bank sticks Neutral	ZD
01:21pm	AstraZeneca Says Tagrisso With Chemotherapy Approved in China	MT

Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified

June 02, 2024 at 05:30 pm IST

June 2 (Reuters) - Daiichi Sankyo Co Ltd:

* ASTRAZENECA: ENHERTU SHOWED MEDIAN PROGRESSION-FREE SURVIVAL OF 13.2 MONTHS IN HR-POSITIVE, HER2-LOW AND HER2-ULTRALOW METASTATIC BREAST CANCER

* ASTRAZENECA: ENHERTU SHOWED MEDIAN PROGRESSION-FREE SURVIVAL AFTER 1 OR MORE LINES OF ENDOCRINE THERAPY

* ASTRAZENECA: DATA FROM TRIALS IN HER2-POSITIVE METASTATIC BREAST CANCER SHOW ENHERTU AS STANDARD OF CARE IN 2ND-LINE SETTING

* ASTRAZENECA: SAFETY PROFILE OF ENHERTU WAS CONSISTENT WITH PREVIOUS BREAST CANCER CLINICAL TRIALS WITH NO NEW SAFETY CONCERNS IDENTIFIED Source text for Eikon: Further company coverage:

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ASTRAZENECA PLC	12,519 GBX	-0.25%	+1.47%	25TCr
	DAIICHI SANKYO CO., LTD.	5,652 JPY	+1.69%	+5.90%	6.65TCr

Latest news about AstraZeneca PLC

ASTRAZENECA : Deutsche Bank sticks Neutral	05:27pm	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	04:51pm	MT
AstraZeneca: Tagrisso approved in China for NSCLC	01:33pm	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	01:12pm	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	12:34pm	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	12:01pm	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	25/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	25/06
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	25/06	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	25/06	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	25/06	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	25/06	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	25/06	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	25/06	RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	25/06	ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL	25/06	CF
AstraZeneca: Tagrisso protocol approved in Japan	25/06	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	25/06	CF
AstraZeneca: conclusive trial in bladder cancer	25/06	CF
AstraZeneca details mixed findings from cancer drug trials	25/06	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	25/06	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	25/06	MT
AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial	25/06	MT
AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial	25/06	DJ

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

159 USD

Average target price

174.4 USD

Spread / Average Target

+9.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+18.13%	25TCr
ELI LILLY AND COMPANY	+55.19%	81TCr
NOVO NORDISK A/S	+45.57%	65TCr
JOHNSON & JOHNSON	-6.09%	35TCr
MERCK & CO., INC.	+21.92%	34TCr
ABBVIE INC.	+10.18%	30TCr
ROCHE HOLDING AG	+2.13%	23TCr
NOVARTIS AG	+13.14%	22TCr
AMGEN INC.	+10.86%	17TCr
PFIZER, INC.	-2.78%	16TCr

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified

Stocks mentioned in the article

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals